당뇨병성 신경병증 시장 : 세계 산업 분석, 규모, 점유율, 성장, 동향 및 예측(2024-2034년)
Diabetic Neuropathy Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2024-2034
상품코드:1487527
리서치사:Transparency Market Research
발행일:2024년 04월
페이지 정보:영문 251 Pages
라이선스 & 가격 (부가세 별도)
한글목차
당뇨병성 신경병증 시장 - 조사 범위
TMR의 세계 당뇨병성 신경병증 시장 조사 보고서는 2024년부터 2034년까지의 예측 기간 동안 시장 지표에 대한 귀중한 통찰력을 얻기 위해 과거뿐만 아니라 현재의 성장 동향과 기회를 조사했습니다. 이 보고서는 2024년을 기준연도로, 2034년을 예측 연도로 하여 2018년부터 2034년까지 세계 당뇨병성 신경병증 시장의 수익과 예측을 제공합니다. 또한 2024년부터 2034년까지 당뇨병성 신경병증 세계 시장의 연평균 성장률(CAGR%)도 제시합니다.
이 보고서는 광범위한 1차 연구, KOL(Key Opinion Leader), 업계 리더 및 오피니언 제조업체와의 인터뷰, 주요 기업의 제품 자료, 연례 보고서, 보도 자료, 관련 문서 및 관련 문헌을 통해 당뇨병성 신경병증 시장을 파악하기 위한 2차 연구를 통해 작성되었습니다. 을 참고했습니다.
시장 현황
2023년 시장 규모
46억 달러
2034년 시장 가치
85억 달러
CAGR
5.5%
이 보고서는 세계 당뇨병성 신경병증 시장의 경쟁 환경에 대해 자세히 연구하고 있습니다. 세계 당뇨병성 신경병증 시장에서 활동하는 주요 기업들이 확인되었으며, 각 기업들은 다양한 속성으로 프로파일링되었습니다. 기업 개요, 재무 상태, 최근 동향 및 SWOT는 이 보고서에서 프로파일링된 세계 당뇨병성 신경병증 시장의 기업 속성입니다.
목차
제1장 서문
제2장 전제조건과 조사 방법
제3장 주요 요약 : 시장
제4장 시장 개요
서론
시장 개요
시장 역학
시장 분석과 예측, 2020-2034년
제5장 주요 인사이트
파이프라인 분석
주요 제품 및 브랜드 분석
주요 M&A
COVID-19 팬데믹의 산업에 대한 영향
제6장 세계 시장 분석과 예측 : 질환 유형별
서론과 정의
주요 조사 결과/발전
시장 매출 예측 : 질환 유형별, 2020년-2034년
말초신경병증
자율신경장애
근위신경장애
국소신경장애
시장의 매력 분석 : 질환 유형별
제7장 세계 시장 분석과 예측 : 치료 유형별
서론과 정의
주요 조사 결과/발전
시장 매출 예측 : 치료 유형별, 2020년-2034년
의약품
진통제
외용약
캡사이신
기타
오피오이드
모르핀
기타
비스테로이드성 항염증제
이부프로펜
나프로키센
기타
항우울제
TCA
Amitriptyline
. Imipramine
기타
SNRI
Duloxetine
기타
SSRI
Citalopram
Paroxetin
기타
항경련제
Gabapentin
Pregabalin
Topimarate
기타
기타 약제
방사선 요법
TENS
기타
물리치료
시장의 매력 분석 : 치료 유형별
제8장 세계 시장 분석과 예측 : 유통 채널별
서론과 정의
주요 조사 결과/발전
시장 매출 예측 : 유통 채널별, 2020년-2034년
병원
진료소
소매 약국
온라인 약국
시장의 매력 분석 : 유통 채널별
제9장 세계 시장 분석과 예측 : 지역별
주요 조사 결과
시장 매출 예측 : 지역별, 2020년-2034년
북미
유럽
아시아태평양
라틴아메리카
중동 및 아프리카
시장의 매력 분석 : 지역별
제10장 북미 시장 분석과 예측
제11장 북유럽주 시장 분석과 예측
제12장 아시아태평양 시장 분석과 예측
제13장 라틴아메리카 시장 분석과 전망
제14장 중동 및 아프리카 시장 분석과 전망
제15장 경쟁 구도
시장 경쟁 매트릭스(기업 Tier별·기업 규모별)
시장 점유율 분석 : 기업별(2023년)
기업 개요
Johnson & Johnson(Janssen Global Services, LLC)
Boehringer Ingelheim GmbH
NeuroMetrix, Inc.
Eli Lilly and Company
GlaxoSmithKline plc
Lupin Limited
Pfizer Inc.
Astellas Pharma Inc.
Glenmark Pharmaceuticals Ltd.
Arbor Pharmaceuticals, LLC
Depomed, Inc.
LSH
영문 목차
영문목차
Diabetic Neuropathy Market - Scope of Report
TMR's report on the global diabetic neuropathy market studies the past as well as the current growth trends and opportunities to gain valuable insights of the indicators of the market during the forecast period from 2024 to 2034. The report provides revenue of the global diabetic neuropathy market for the period 2018-2034, considering 2024 as the base year and 2034 as the forecast year. The report also provides the compound annual growth rate (CAGR %) of the global diabetic neuropathy market from 2024 to 2034.
The report has been prepared after an extensive research. Primary research involved bulk of the research efforts, wherein analysts carried out interviews with key opinion leaders, industry leaders, and opinion makers. Secondary research involved referring to key players' product literature, annual reports, press releases, and relevant documents to understand the diabetic neuropathy market.
Market Snapshot
Market Value in 2023
US$ 4.6 Bn
Market Value in 2034
US$ 8.5 Bn
CAGR
5.5%
Secondary research also included Internet sources, statistical data from government agencies, websites, and trade associations. Analysts employed a combination of top-down and bottom-up approaches to study various attributes of the global diabetic neuropathy market.
The report includes an elaborate executive summary, along with a snapshot of the growth behavior of various segments included in the scope of the study. Moreover, the report throws light on the changing competitive dynamics in the global diabetic neuropathy market. These serve as valuable tools for existing market players as well as for entities interested in participating in the global diabetic neuropathy market.
The report delves into the competitive landscape of the global diabetic neuropathy market. Key players operating in the global diabetic neuropathy market have been identified and each one of these has been profiled in terms of various attributes. Company overview, financial standings, recent developments, and SWOT are the attributes of players in the global diabetic neuropathy market profiled in this report.
Key Questions Answered in Global diabetic neuropathy Market Report:
What is the sales/revenue generated by diabetic neuropathy across all regions during the forecast period?
What are the opportunities in the global diabetic neuropathy market?
What are the major drivers, restraints, opportunities, and threats in the market?
Which regional market is set to expand at the fastest CAGR during the forecast period?
Which segment is expected to generate the highest revenue globally in 2034?
Which segment is projected to expand at the highest CAGR during the forecast period?
What are the market positions of different companies operating in the global market?
Diabetic Neuropathy Market - Research Objectives and Research Approach
The comprehensive report on the global diabetic neuropathy market begins with an overview, followed by the scope and objectives of the study. The report provides detailed explanation of the objectives behind this study and key vendors and distributors operating in the market and regulatory scenario for approval of products.
For reading comprehensibility, the report has been compiled in a chapter-wise layout, with each section divided into smaller ones. The report comprises an exhaustive collection of graphs and tables that are appropriately interspersed. Pictorial representation of actual and projected values of key segments is visually appealing to readers. This also allows comparison of the market shares of key segments in the past and at the end of the forecast period.
The report analyzes the global diabetic neuropathy market in terms of product, end-user, and region. Key segments under each criterion have been studied at length, and the market share for each of these at the end of 2034 has been provided. Such valuable insights enable market stakeholders in making informed business decisions for investment in the global diabetic neuropathy market.
Table of Contents
1. Preface
1.1. Market Definition and Scope
1.2. Market Segmentation
1.3. Key Research Objectives
1.4. Research Highlights
2. Assumptions and Research Methodology
3. Executive Summary: Diabetic Neuropathy Market
4. Market Overview
4.1. Introduction
4.1.1. Product Definition
4.1.2. Industry Evolution/Developments
4.2. Overview
4.3. Market Dynamics
4.3.1. Drivers
4.3.2. Restraints
4.3.3. Opportunities
4.4. Diabetic Neuropathy Market Analysis and Forecast, 2020-2034
5. Key Insights
5.1. Pipeline Analysis
5.2. Key Product /Brand Analysis
5.3. Key Mergers & Acquisitions
5.4. COVID-19 Pandemic Impact on Industry
6. Global Diabetic Neuropathy Market Analysis and Forecast, by Disorder Type
6.1. Introduction & Definition
6.2. Key Findings/Developments
6.3. Market Value Forecast, by Disorder Type, 2020-2034
6.3.1. Peripheral Neuropathy
6.3.2. Autonomic Neuropathy
6.3.3. Proximal Neuropathy
6.3.4. Focal Neuropathy
6.4. Market Attractiveness Analysis, by Disorder Type
7. Global Diabetic Neuropathy Market Analysis and Forecast, by Treatment Type
7.1. Introduction & Definition
7.2. Key Findings/Developments
7.3. Market Value Forecast, by Treatment Type, 2020-2034
7.3.1. Drugs
7.3.1.1. Analgesics
7.3.1.1.1. Topical
7.3.1.1.1.1. Capsaicin
7.3.1.1.1.2. Others
7.3.1.1.2. Opioids
7.3.1.1.2.1. Morphine
7.3.1.1.2.2. Others
7.3.1.1.3. NSAIDs
7.3.1.1.3.1. Ibuprofen
7.3.1.1.3.2. Naproxen
7.3.1.1.3.3. Others
7.3.1.2. Antidepressants
7.3.1.2.1. TCAs
7.3.1.2.1.1. Amitriptyline
7.3.1.2.1.2. Imipramine
7.3.1.2.1.3. Others
7.3.1.2.2. SNRIs
7.3.1.2.2.1. Duloxetine
7.3.1.2.2.2. Others
7.3.1.2.3. SSRIs
7.3.1.2.3.1. Citalopram
7.3.1.2.3.2. Paroxetin
7.3.1.2.3.3. Others
7.3.1.3. Anticonvulsants
7.3.1.3.1. Gabapentin
7.3.1.3.2. Pregabalin
7.3.1.3.3. Topimarate
7.3.1.3.4. Others
7.3.1.4. Other Drugs
7.3.2. Radiotherapy
7.3.2.1. TENS
7.3.2.2. Others
7.3.3. Physiotherapy
7.4. Market Attractiveness Analysis, by Treatment Type
8. Global Diabetic Neuropathy Market Analysis and Forecast, by Distribution Channel
8.1. Introduction & Definition
8.2. Key Findings/Developments
8.3. Market Value Forecast, by Distribution Channel, 2020-2034
8.3.1. Hospitals
8.3.2. Clinics
8.3.3. Retail Pharmacies
8.3.4. Online Pharmacies
8.4. Market Attractiveness Analysis, by Distribution Channel
9. Global Diabetic Neuropathy Market Analysis and Forecast, by Region
9.1. Key Findings
9.2. Market Value Forecast, by Region, 2020-2034
9.2.1. North America
9.2.2. Europe
9.2.3. Asia Pacific
9.2.4. Latin America
9.2.5. Middle East & Africa
9.3. Market Attractiveness Analysis, by Region
10. North America Diabetic Neuropathy Market Analysis and Forecast
10.1. Introduction
10.2. Key Findings
10.3. Market Value Forecast, by Disorder Type, 2020-2034
10.3.1. Peripheral Neuropathy
10.3.2. Autonomic Neuropathy
10.3.3. Proximal Neuropathy
10.3.4. Focal Neuropathy
10.4. Market Value Forecast, by Treatment Type, 2020-2034
10.4.1. Drugs
10.4.1.1. Analgesics
10.4.1.1.1. Topical
10.4.1.1.1.1. Capsaicin
10.4.1.1.1.2. Others
10.4.1.1.2. Opioids
10.4.1.1.2.1. Morphine
10.4.1.1.2.2. Others
10.4.1.1.3. NSAIDs
10.4.1.1.3.1. Ibuprofen
10.4.1.1.3.2. Naproxen
10.4.1.1.3.3. Others
10.4.1.2. Antidepressants
10.4.1.2.1. TCAs
10.4.1.2.1.1. Amitriptyline
10.4.1.2.1.2. Imipramine
10.4.1.2.1.3. Others
10.4.1.2.2. SNRIs
10.4.1.2.2.1. Duloxetine
10.4.1.2.2.2. Others
10.4.1.2.3. SSRIs
10.4.1.2.3.1. Citalopram
10.4.1.2.3.2. Paroxetin
10.4.1.2.3.3. Others
10.4.1.3. Anticonvulsants
10.4.1.3.1. Gabapentin
10.4.1.3.2. Pregabalin
10.4.1.3.3. Topimarate
10.4.1.3.4. Others
10.4.1.4. Other Drugs
10.4.2. Radiotherapy
10.4.2.1. TENS
10.4.2.2. Others
10.4.3. Physiotherapy
10.5. Market Value Forecast, by Distribution Channel, 2020-2034
10.5.1. Hospitals
10.5.2. Clinics
10.5.3. Retail Pharmacies
10.5.4. Online Pharmacies
10.6. Market Value Forecast, by Country, 2020-2034
10.6.1. U.S.
10.6.2. Canada
10.7. Market Attractiveness Analysis
10.7.1. By Disorder Type
10.7.2. By Treatment Type
10.7.3. By Distribution Channel
10.7.4. By Country
11. Europe Diabetic Neuropathy Market Analysis and Forecast
11.1. Introduction
11.2. Key Findings
11.3. Market Value Forecast, by Disorder Type, 2020-2034
11.3.1. Peripheral Neuropathy
11.3.2. Autonomic Neuropathy
11.3.3. Proximal Neuropathy
11.3.4. Focal Neuropathy
11.4. Market Value Forecast, by Treatment Type, 2020-2034
11.4.1. Drugs
11.4.1.1. Analgesics
11.4.1.1.1. Topical
11.4.1.1.1.1. Capsaicin
11.4.1.1.1.2. Others
11.4.1.1.2. Opioids
11.4.1.1.2.1. Morphine
11.4.1.1.2.2. Others
11.4.1.1.3. NSAIDs
11.4.1.1.3.1. Ibuprofen
11.4.1.1.3.2. Naproxen
11.4.1.1.3.3. Others
11.4.1.2. Antidepressants
11.4.1.2.1. TCAs
11.4.1.2.1.1. Amitriptyline
11.4.1.2.1.2. Imipramine
11.4.1.2.1.3. Others
11.4.1.2.2. SNRIs
11.4.1.2.2.1. Duloxetine
11.4.1.2.2.2. Others
11.4.1.2.3. SSRIs
11.4.1.2.3.1. Citalopram
11.4.1.2.3.2. Paroxetin
11.4.1.2.3.3. Others
11.4.1.3. Anticonvulsants
11.4.1.3.1. Gabapentin
11.4.1.3.2. Pregabalin
11.4.1.3.3. Topimarate
11.4.1.3.4. Others
11.4.1.4. Other Drugs
11.4.2. Radiotherapy
11.4.2.1. TENS
11.4.2.2. Others
11.4.3. Physiotherapy
11.5. Market Value Forecast, by Distribution Channel, 2020-2034
11.5.1. Hospitals
11.5.2. Clinics
11.5.3. Retail Pharmacies
11.5.4. Online Pharmacies
11.6. Market Value Forecast, by Country/Sub-region, 2020-2034
11.6.1. Germany
11.6.2. U.K.
11.6.3. France
11.6.4. Italy
11.6.5. Spain
11.6.6. Rest of Europe
11.7. Market Attractiveness Analysis
11.7.1. By Disorder Type
11.7.2. By Treatment Type
11.7.3. By Distribution Channel
11.7.4. By Country/Sub-region
12. Asia Pacific Diabetic Neuropathy Market Analysis and Forecast
12.1. Introduction
12.2. Key Findings
12.3. Market Value Forecast, by Disorder Type, 2020-2034
12.3.1. Peripheral Neuropathy
12.3.2. Autonomic Neuropathy
12.3.3. Proximal Neuropathy
12.3.4. Focal Neuropathy
12.4. Market Value Forecast, by Treatment Type, 2020-2034
12.4.1. Drugs
12.4.1.1. Analgesics
12.4.1.1.1. Topical
12.4.1.1.1.1. Capsaicin
12.4.1.1.1.2. Others
12.4.1.1.2. Opioids
12.4.1.1.2.1. Morphine
12.4.1.1.2.2. Others
12.4.1.1.3. NSAIDs
12.4.1.1.3.1. Ibuprofen
12.4.1.1.3.2. Naproxen
12.4.1.1.3.3. Others
12.4.1.2. Antidepressants
12.4.1.2.1. TCAs
12.4.1.2.1.1. Amitriptyline
12.4.1.2.1.2. Imipramine
12.4.1.2.1.3. Others
12.4.1.2.2. SNRIs
12.4.1.2.2.1. Duloxetine
12.4.1.2.2.2. Others
12.4.1.2.3. SSRIs
12.4.1.2.3.1. Citalopram
12.4.1.2.3.2. Paroxetin
12.4.1.2.3.3. Others
12.4.1.3. Anticonvulsants
12.4.1.3.1. Gabapentin
12.4.1.3.2. Pregabalin
12.4.1.3.3. Topimarate
12.4.1.3.4. Others
12.4.1.4. Other Drugs
12.4.2. Radiotherapy
12.4.2.1. TENS
12.4.2.2. Others
12.4.3. Physiotherapy
12.5. Market Value Forecast, by Distribution Channel, 2020-2034
12.5.1. Hospitals
12.5.2. Clinics
12.5.3. Retail Pharmacies
12.5.4. Online Pharmacies
12.6. Market Value Forecast, by Country/Sub-region, 2020-2034
12.6.1. China
12.6.2. Japan
12.6.3. India
12.6.4. Australia & New Zealand
12.6.5. Rest of Asia Pacific
12.7. Market Attractiveness Analysis
12.7.1. By Disorder Type
12.7.2. By Treatment Type
12.7.3. By Distribution Channel
12.7.4. By Country/Sub-region
13. Latin America Diabetic Neuropathy Market Analysis and Forecast
13.1. Introduction
13.2. Key Findings
13.3. Market Value Forecast, by Disorder Type, 2020-2034
13.3.1. Peripheral Neuropathy
13.3.2. Autonomic Neuropathy
13.3.3. Proximal Neuropathy
13.3.4. Focal Neuropathy
13.4. Market Value Forecast, by Treatment Type, 2020-2034
13.4.1. Drugs
13.4.1.1. Analgesics
13.4.1.1.1. Topical
13.4.1.1.1.1. Capsaicin
13.4.1.1.1.2. Others
13.4.1.1.2. Opioids
13.4.1.1.2.1. Morphine
13.4.1.1.2.2. Others
13.4.1.1.3. NSAIDs
13.4.1.1.3.1. Ibuprofen
13.4.1.1.3.2. Naproxen
13.4.1.1.3.3. Others
13.4.1.2. Antidepressants
13.4.1.2.1. TCAs
13.4.1.2.1.1. Amitriptyline
13.4.1.2.1.2. Imipramine
13.4.1.2.1.3. Others
13.4.1.2.2. SNRIs
13.4.1.2.2.1. Duloxetine
13.4.1.2.2.2. Others
13.4.1.2.3. SSRIs
13.4.1.2.3.1. Citalopram
13.4.1.2.3.2. Paroxetin
13.4.1.2.3.3. Others
13.4.1.3. Anticonvulsants
13.4.1.3.1. Gabapentin
13.4.1.3.2. Pregabalin
13.4.1.3.3. Topimarate
13.4.1.3.4. Others
13.4.1.4. Other Drugs
13.4.2. Radiotherapy
13.4.2.1. TENS
13.4.2.2. Others
13.4.3. Physiotherapy
13.5. Market Value Forecast, by Distribution Channel, 2020-2034
13.5.1. Hospitals
13.5.2. Clinics
13.5.3. Retail Pharmacies
13.5.4. Online Pharmacies
13.6. Market Value Forecast, by Country/Sub-region, 2020-2034
13.6.1. Brazil
13.6.2. Mexico
13.6.3. Rest of Latin America
13.7. Market Attractiveness Analysis
13.7.1. By Disorder Type
13.7.2. By Treatment Type
13.7.3. By Distribution Channel
13.7.4. By Country/Sub-region
14. Middle East & Africa Diabetic Neuropathy Market Analysis and Forecast
14.1. Introduction
14.2. Key Findings
14.3. Market Value Forecast, by Disorder Type, 2020-2034
14.3.1. Peripheral Neuropathy
14.3.2. Autonomic Neuropathy
14.3.3. Proximal Neuropathy
14.3.4. Focal Neuropathy
14.4. Market Value Forecast, by Treatment Type, 2020-2034
14.4.1. Drugs
14.4.1.1. Analgesics
14.4.1.1.1. Topical
14.4.1.1.1.1. Capsaicin
14.4.1.1.1.2. Others
14.4.1.1.2. Opioids
14.4.1.1.2.1. Morphine
14.4.1.1.2.2. Others
14.4.1.1.3. NSAIDs
14.4.1.1.3.1. Ibuprofen
14.4.1.1.3.2. Naproxen
14.4.1.1.3.3. Others
14.4.1.2. Antidepressants
14.4.1.2.1. TCAs
14.4.1.2.1.1. Amitriptyline
14.4.1.2.1.2. Imipramine
14.4.1.2.1.3. Others
14.4.1.2.2. SNRIs
14.4.1.2.2.1. Duloxetine
14.4.1.2.2.2. Others
14.4.1.2.3. SSRIs
14.4.1.2.3.1. Citalopram
14.4.1.2.3.2. Paroxetin
14.4.1.2.3.3. Others
14.4.1.3. Anticonvulsants
14.4.1.3.1. Gabapentin
14.4.1.3.2. Pregabalin
14.4.1.3.3. Topimarate
14.4.1.3.4. Others
14.4.1.4. Other Drugs
14.4.2. Radiotherapy
14.4.2.1. TENS
14.4.2.2. Others
14.4.3. Physiotherapy
14.5. Market Value Forecast, by Distribution Channel, 2020-2034
14.5.1. Hospitals
14.5.2. Clinics
14.5.3. Retail Pharmacies
14.5.4. Online Pharmacies
14.6. Market Value Forecast, by Country/Sub-region, 2020-2034
14.6.1. GCC Countries
14.6.2. South Africa
14.6.3. Rest of Middle East & Africa
14.7. Market Attractiveness Analysis
14.7.1. By Disorder Type
14.7.2. By Treatment Type
14.7.3. By Distribution Channel
14.7.4. By Country/Sub-region
15. Competition Landscape
15.1. Market Player - Competitive Matrix (by Tier and Size of Companies)
15.2. Market Share Analysis, by Company (2023)
15.3. Company Profiles
15.3.1. Johnson & Johnson (Janssen Global Services, LLC)
